Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.55 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.48 |
| ▸ | KDR | P35968 | 2/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.48 |
| ▸ | AMY1A | P0DUB6 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 8/20 | 0.43 |
| ▸ | RAB9A | P51151 | 6/20 | 0.43 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.43 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | HPGD | P15428 | 4/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.42 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3536522 | 0.83 | GSK3B (0.56) | GSK3BFGFR1KDRPDGFRBNPC1 | |
| SCHEMBL3536815 | 0.83 | GSK3B (0.55) | GSK3BFGFR1KDRPDGFRBAMY1A | |
| SCHEMBL3540544 | 0.82 | GSK3B (0.54) | GSK3BFGFR1KDRPDGFRBAMY1A | |
| SCHEMBL3540379 | 0.80 | GSK3B (0.53) | GSK3BFGFR1KDRPDGFRBNPC1 | |
| SCHEMBL3534156 | 0.80 | GSK3B (0.48) | GSK3BFGFR1KDRPDGFRBNPC1 | |
| SCHEMBL3540845 | 0.79 | GSK3B (0.61) | GSK3BFGFR1KDRPDGFRBNPC1 | |
| SCHEMBL3542238 | 0.79 | PDGFRB (0.48) | GSK3BFGFR1KDRPDGFRBRAB9A | |
| SCHEMBL4809631 | 0.77 | NPC1 (0.69) | GSK3BKDRAMY1ANPC1RAB9A | |
| SCHEMBL3536964 | 0.77 | GSK3B (0.49) | GSK3BFGFR1KDRPDGFRBNPC1 | |
| SCHEMBL3539324 | 0.77 | GSK3B (0.58) | GSK3BFGFR1KDRPDGFRBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7727989-B2 | 4-benzimidazol-2-yl-pyridazine-3-one-derivatives, production and use thereof in medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-06-01 | — | — | US | claimed |
| US-7727989-B2 | 4-benzimidazol-2-yl-pyridazine-3-one-derivatives, production and use thereof in medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-06-01 | — | — | US | disclosed |
| US-7727989-B2 | 4-benzimidazol-2-yl-pyridazine-3-one-derivatives, production and use thereof in medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-06-01 | — | — | US | disclosed |
| US-7727989-B2 | 4-benzimidazol-2-yl-pyridazine-3-one-derivatives, production and use thereof in medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-06-01 | — | — | US | disclosed |
| EP-1725543-B1 | 4-BENZIMIDAZOL-2-YL-PYRIDAZINE-3-ONE-DERIVATIVES, PRODUCTION AND USE THEREOF IN MEDICAMENTS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-11-28 | — | — | EP | disclosed |
| EP-1725543-B1 | 4-BENZIMIDAZOL-2-YL-PYRIDAZINE-3-ONE-DERIVATIVES, PRODUCTION AND USE THEREOF IN MEDICAMENTS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-11-28 | — | — | EP | disclosed |
| US-20070072866-A1 | 4-BENZIMIDAZOL-2-YL-PYRIDAZINE-3-ONE-DERIVATIVES, PRODUCTION AND USE THEREOF IN MEDICAMENTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-03-29 | — | — | US | disclosed |
| US-20070072866-A1 | 4-BENZIMIDAZOL-2-YL-PYRIDAZINE-3-ONE-DERIVATIVES, PRODUCTION AND USE THEREOF IN MEDICAMENTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-03-29 | — | — | US | disclosed |
| US-20070072866-A1 | 4-BENZIMIDAZOL-2-YL-PYRIDAZINE-3-ONE-DERIVATIVES, PRODUCTION AND USE THEREOF IN MEDICAMENTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-03-29 | — | — | US | disclosed |
| EP-1725543-A1 | 4-BENZIMIDAZOL-2-YL-PYRIDAZINE-3-ONE-DERIVATIVES, PRODUCTION AND USE THEREOF IN MEDICAMENTS | Sanofi-Aventis Deutschland GmbH (DE) | 2006-11-29 | — | — | EP | disclosed |
| WO-2005085230-A1 | 4-BENZIMIDAZOL-2-YL-PYRIDAZINE-3-ONE-DERIVATIVES, PRODUCTION AND USE THEREOF IN MEDICAMENTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-09-15 | — | — | WO | disclosed |
| WO-2005085230-A1 | 4-BENZIMIDAZOL-2-YL-PYRIDAZINE-3-ONE-DERIVATIVES, PRODUCTION AND USE THEREOF IN MEDICAMENTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072866-A1 | 4-BENZIMIDAZOL-2-YL-PYRIDAZINE-3-ONE-DERIVATIVES, PRODUCTION AND USE THEREOF IN MEDICAMENTS | GSK3B, GSK3A, PYGB | GSK3B 1/4885FGFR1 1854/4885KDR 2532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.